Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease
Status:
Withdrawn
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
After 6 weeks of maximal Ranolazine therapy, tissue hemoglobin desaturation kinetics will
change compared to placebo in patients with chronic angina and peripheral arterial disease.